116 results about "Drug conjugation" patented technology

A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):

This invention relates to antibody-drug conjugates and their uses. An antibody-drug conjugate having a structure represented by formula (I) is provided: Ab-(L-D) n (I), wherein Ab is an antibody against the interleukin-6 receptor or an antigen-binding fragment thereof, said antibody or antigen-binding fragment comprising at least one light chain and at least one heavy chain as described herein, and the use of the antibody-drug conjugate. The antibody-drug conjugate of the present invention can significantly reduce the dosage, improve patient tolerability, and reduce adverse reactions.

Provided are bispecific antibody-drug conjugates targeting EGFR and HER3, pharmaceutical compositions comprising the conjugates, their use for treating or preventing diseases or conditions associated with EGFR and / or HER3 activity, particularly EGFR and / or HER3-positive tumors, and their use in the preparation of pharmaceuticals for treating or preventing diseases or conditions associated with EGFR and / or HER3 activity, particularly EGFR and / or HER3-positive tumors.

This invention relates to mini-binding proteins targeting Nectin-4, their drug conjugates, and their applications. The present invention has screened and obtained a class of mini-binding proteins specifically targeting Nectin-4, whose amino acid sequences include any one of SEQ ID Nos. 1-6. This application further conjugates the mini-protein conjugates with the microtubule inhibitor VcMMAE to generate mini-protein drug conjugates (MPDCs), which can target and kill Nectin-4 positive tumor cells.

A camptothecin conjugate and a preparation method thereof. The camptothecin conjugate has excellent drug activity and kinetic characteristics, and is suitable for preparing a drug for treating tumor-related diseases.

The present invention relates to a modified oligonucleotide including at least one modified nucleic acid, and a modified oligonucleotide-drug conjugate including a drug conjugated to the modified oligonucleotide. The modified oligonucleotide-drug conjugate of the present invention exhibits high stability in the body and may exhibit an excellent anticancer effect.

This application provides a new NMT inhibitor and an antibody-drug conjugate (ADC) that comprises the NMT inhibitor as the payload tethered to an antibody, as well as a method for treating or preventing a disease or disorder associated with NMT, such as cancer associated with a cancerous cell that expresses HER2, CD19, CD20, or CD276 / 87-H3).

The present disclosure relates to the antibodies specific targeting CD142, antibody-drug conjugates, preparations and uses thereof. The antibody or antigen-binding fragment thereof binding to CD142 is covalently linked to a cytotoxic payload through a linker. The antibody or antigen-binding fragment thereof binding to CD142 and the antibody-drug conjugate exhibit cytotoxic effects on tumor cells.

The present invention relates to dual payload antibody drug conjugates comprising at least one topoisomerase inhibitor and at least one DNA damage response (DDR) inhibitor, pharmaceutical compositions thereof, and uses of the antibody drug conjugates and compositions thereof in the treatment of diseases and conditions, including proliferative diseases.

This invention relates to the use of PD-L1 binding molecules in improving the stability of protein-drug conjugate formulations. It also relates to a pharmaceutical composition comprising a PD-L1 binding molecule and a protein-drug conjugate, and discloses its antitumor use.

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

A device may receive, by the computer system, a digital chemical structure for each of a plurality of ligand-drug conjugate compounds. A device may calculate by said one or more processors, an aggregation number for each of said plurality of ligand-drug conjugate compounds. A device may rank, by the computer system, at least a portion of said plurality of ligand-drug conjugate compounds based on said aggregation number. A device may identify, by the computer system, a plurality of low aggregation ligand-drug conjugate compounds based on said ranking, wherein said plurality of low aggregation ligand-drug conjugate compounds is a portion of said plurality of ligand-drug conjugate compounds having an aggregation number indicative of a predicted molecular aggregation lower than the predicted molecular aggregation of a remaining ligand-drug conjugate compounds within said plurality of ligand-drug conjugate compounds.

Disclosed are ligand drug conjugates (LDCs) for treating cancers and other diseases, and compounds useful for preparing the LDCs.

The present disclosure relates to pharmaceutical and diagnostic compositions comprising macropinocytosis-selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain linked to a pharmaceutically active or diagnostic moiety. The present disclosure also relates to methods of treatment and diagnosis comprising administering to a subject in need thereof a pharmaceutical composition described herein. TIFF2023551388000007.tif63166

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The present disclosure relates to an antibody, a payload and a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.

The present invention provides a pharmaceutical composition containing an antibody-drug conjugate useful for the treatment of cancer. [Solution] This disclosure relates to an antibody-drug conjugate for the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting the glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugate consists of an exatechcan derivative coupled to the anti-MUC1 antibody.

The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

This invention provides an antitumor drug with excellent therapeutic effects, exhibiting superior antitumor efficacy and safety. It also provides an anti-cadherin 17 antibody comprising a heavy chain variable region and a light chain variable region, a drug conjugate thereof, and a composition containing an anti-cadherin 17 antibody or a drug conjugate thereof, and their use as a drug.

The invention relates to prostate specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates (ADCs). The invention provides a method for treating a subject using anti-PSMA ADCs in inhibiting, preventing or treating PSMA-related diseases or cancers, including prostate cancer. The disclosure also provides pharmaceutical compositions containing anti-PSMA ADCs suitable for administration to human subjects.

The present disclosure relates to conjugates of camptothecin analogs of the formula T-(L-D) m with a cell binding molecule. The present disclosure also provides methods for preparing conjugates of camptothecin analogs with cell binding agents, and methods of using the conjugates in tumor-targeted therapy.

This invention relates to antibodies and antibody-drug conjugates, and more particularly to antibodies targeting Claudin18.2 (CLDN18.2) and antibody-drug conjugates (ADCs), as well as compositions containing said antibodies and ADC molecules and their therapeutic applications.

This invention relates to antigen-binding molecules and antibody-drug conjugates, and more particularly to antibodies and antibody-drug conjugates (ADCs) targeting CLDN18.2 and / or CDH17, as well as compositions containing said antibodies or ADCs and their therapeutic applications.

The present invention relates to antigen binding molecules and antibody-drug conjugates, more specifically to antibodies and antibody-drug conjugates (ADCs) targeting CDH17 and / or EGFR and compositions containing said antigen binding molecules or ADCs and therapeutic uses thereof.

Provided herein are novel antibody-agent conjugates formed by the introduction of methionine residues to antibody scaffold light or heavy chains at select positions, followed by conjugation of the agent to the methionine, for example, by oxaziridine chemistries. Methionine substitutions at the targeted positions enable highly efficient functionalization to form very stable conjugates, including conjugates suitable for in vivo use. The positions were identified for the trastuzumab and other related scaffolds which can be engineered for affinity to any target antigen. The conjugates include ADCs and detections agents. Also disclosed are novel oxaziridine reagents for conjugation to methionines in proteins.

The present invention relates to an antigen-binding molecule and an antibody-drug conjugate, and more specifically to an antibody and an antibody-drug conjugate (ADC) targeting CLDN18.2 and / or CDH17, and a composition containing the antibody or ADC and the therapeutic use thereof.

This application provides a new NMT inhibitor and an antibody-drug conjugate (ADC) that comprises the NMT inhibitor as the payload tethered to an antibody, as well as a method for treating or preventing a disease or disorder associated with NMT, such as cancer associated with a cancerous cell that expresses HER2, CD 19, CD20, or CD276 / 87-H3).

The present application discloses an antibody drug conjugate, which comprises the structure of the following formula 1 wherein, Ab is an antibody or antibody fragment which targets ITGA2, and j is 1 to 8, preferably 4 to 8. The antibody-drug conjugate of the application has a high specificity binding ability to tumor cells expressing ITGA2 protein, thereby achieving an excellent killing effect on tumor cells.

The present disclosure relates to an antibody binding to CD22, a bispecific antibody including the same, a chimeric antigen receptor, an antibody-drug conjugate, and uses thereof. According to one aspect, effective anticancer effects can be provided even for patients who are refractory to CD19-targeted therapies. Further, when using CD22 CAR NK cells or bispecific CD22 / CD19 CAR NK cells, significantly enhanced reduction of cancer cells can be achieved.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.